Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.

Gong X, Du J, Parsons SH, Merzoug FF, Webster Y, Iversen PW, Chio LC, Van Horn RD, Lin X, Blosser W, Han B, Jin S, Yao S, Bian H, Ficklin C, Fan L, Kapoor A, Antonysamy S, Mc Nulty AM, Froning K, Manglicmot D, Pustilnik A, Weichert K, Wasserman SR, Dowless M, Marugán C, Baquero C, Lallena MJ, Eastman SW, Hui YH, Dieter MZ, Doman T, Chu S, Qian HR, Ye XS, Barda DA, Plowman GD, Reinhard C, Campbell RM, Henry JR, Buchanan SG.

Cancer Discov. 2019 Feb;9(2):248-263. doi: 10.1158/2159-8290.CD-18-0469. Epub 2018 Oct 29.

PMID:
30373917
2.

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.

Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, Clawson DK, Britt KS, Anderson BD, Beight DW, Desaiah D, Lahn MM, Benhadji KA, Lallena MJ, Holmgaard RB, Xu X, Zhang F, Manro JR, Iversen PW, Iyer CV, Brekken RA, Kalos MD, Driscoll KE.

Oncotarget. 2017 Dec 31;9(6):6659-6677. doi: 10.18632/oncotarget.23795. eCollection 2018 Jan 23.

3.

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.

Gong X, Litchfield LM, Webster Y, Chio LC, Wong SS, Stewart TR, Dowless M, Dempsey J, Zeng Y, Torres R, Boehnke K, Mur C, Marugán C, Baquero C, Yu C, Bray SM, Wulur IH, Bi C, Chu S, Qian HR, Iversen PW, Merzoug FF, Ye XS, Reinhard C, De Dios A, Du J, Caldwell CW, Lallena MJ, Beckmann RP, Buchanan SG.

Cancer Cell. 2017 Dec 11;32(6):761-776.e6. doi: 10.1016/j.ccell.2017.11.006.

4.

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer.

Torres-Guzmán R, Calsina B, Hermoso A, Baquero C, Alvarez B, Amat J, McNulty AM, Gong X, Boehnke K, Du J, de Dios A, Beckmann RP, Buchanan S, Lallena MJ.

Oncotarget. 2017 May 10;8(41):69493-69507. doi: 10.18632/oncotarget.17778. eCollection 2017 Sep 19.

5.

Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures.

Boehnke K, Iversen PW, Schumacher D, Lallena MJ, Haro R, Amat J, Haybaeck J, Liebs S, Lange M, Schäfer R, Regenbrecht CR, Reinhard C, Velasco JA.

J Biomol Screen. 2016 Oct;21(9):931-41. doi: 10.1177/1087057116650965. Epub 2016 May 27.

6.

Phenotypic Screening Approaches to Develop Aurora Kinase Inhibitors: Drug Discovery Perspectives.

Marugán C, Torres R, Lallena MJ.

Front Oncol. 2016 Jan 7;5:299. doi: 10.3389/fonc.2015.00299. eCollection 2015. Review.

7.

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs.

Sánchez-Martínez C, Gelbert LM, Lallena MJ, de Dios A.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3420-35. doi: 10.1016/j.bmcl.2015.05.100. Epub 2015 Jun 6. Review.

PMID:
26115571
8.

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.

Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A.

Invest New Drugs. 2014 Oct;32(5):825-37. doi: 10.1007/s10637-014-0120-7. Epub 2014 Jun 13.

9.

A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models.

Yin T, Lallena MJ, Kreklau EL, Fales KR, Carballares S, Torrres R, Wishart GN, Ajamie RT, Cronier DM, Iversen PW, Meier TI, Foreman RT, Zeckner D, Sissons SE, Halstead BW, Lin AB, Donoho GP, Qian Y, Li S, Wu S, Aggarwal A, Ye XS, Starling JJ, Gaynor RB, de Dios A, Du J.

Mol Cancer Ther. 2014 Jun;13(6):1442-56. doi: 10.1158/1535-7163.MCT-13-0849. Epub 2014 Mar 31.

10.

Multiparametric cell-based assay for the evaluation of transcription inhibition by high-content imaging.

Torres-Guzmán R, Chu S, Velasco JA, Lallena MJ.

J Biomol Screen. 2013 Jun;18(5):556-66. doi: 10.1177/1087057112472539. Epub 2013 Jan 10.

PMID:
23307837
11.

Splicing regulation at the second catalytic step by Sex-lethal involves 3' splice site recognition by SPF45.

Lallena MJ, Chalmers KJ, Llamazares S, Lamond AI, Valcárcel J.

Cell. 2002 May 3;109(3):285-96.

12.

Nuclear and Cytoplasmic Localization Signals in Protein 4.1R.

Correas I, Pérez-Ferreiro CM, Lallena MJ, Luque CM.

Cell Mol Biol Lett. 2001;6(2):195. No abstract available.

PMID:
11544648
13.

Requirement of Hsp90 for centrosomal function reflects its regulation of Polo kinase stability.

de Cárcer G, do Carmo Avides M, Lallena MJ, Glover DM, González C.

EMBO J. 2001 Jun 1;20(11):2878-84.

14.
15.

The N-terminal 209-aa domain of high molecular-weight 4.1R isoforms abrogates 4.1R targeting to the nucleus.

Luque CM, Lallena MJ, Pérez-Ferreiro CM, de Isidro Y, De Cárcer G, Alonso MA, Correas I.

Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14925-30.

16.
17.

The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation.

Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J.

EMBO J. 1999 Jun 1;18(11):3044-53.

18.

Activation of IkappaB kinase beta by protein kinase C isoforms.

Lallena MJ, Diaz-Meco MT, Bren G, Payá CV, Moscat J.

Mol Cell Biol. 1999 Mar;19(3):2180-8.

19.

Functional association of nuclear protein 4.1 with pre-mRNA splicing factors.

Lallena MJ, Martínez C, Valcárcel J, Correas I.

J Cell Sci. 1998 Jul 30;111 ( Pt 14):1963-71.

20.

An alternative domain determines nuclear localization in multifunctional protein 4.1.

Luque CM, Lallena MJ, Alonso MA, Correas I.

J Biol Chem. 1998 May 8;273(19):11643-9.

21.
22.

Protein 4.1 is a component of the nuclear matrix of mammalian cells.

de Cárcer G, Lallena MJ, Correas I.

Biochem J. 1995 Dec 15;312 ( Pt 3):871-7.

Supplemental Content

Loading ...
Support Center